GlassScriptPhysician profile
Stephanny Parker
NPI 1043978703
$9,628.97
in general payments reported to CMS, 2019-2025
26 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,698 · 2023: $3,740 · 2024: $3,924 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,883 · Education: $48.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,883.17 |
| Education | $48.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,106.78 | 2022-2024 | Rexulti, Nuedexta, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $790.42 | 2022-2024 | Spravato, Invega Sustenna, Invega |
| Alkermes, INC. | $766.13 | 2022-2024 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $761.60 | 2022-2025 | |
| Ironshore Pharmaceuticals INC. | $724.30 | 2022-2024 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $694.22 | 2022-2024 | Caplyta |
| Lundbeck LLC | $523.79 | 2022-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $517.82 | 2023-2024 | Austedo Xr, Uzedy, Austedo |
| Corium, LLC | $474.60 | 2022-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $427.09 | 2022-2024 | Fanapt, Hetlioz |
| Validus Pharmaceuticals LLC | $397.08 | 2024 | Equetro |
| Almatica Pharma LLC | $340.43 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Supernus Pharmaceuticals, INC. | $323.29 | 2023-2024 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $294.11 | 2022-2024 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $249.87 | 2024-2025 | Cobenfy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $217.77 | 2022-2023 | Perseris |
| Neurocrine Biosciences, INC. | $186.20 | 2022-2024 | Ingrezza |
| Merck Sharp & Dohme LLC | $168.87 | 2022-2023 | Belsomra |
| Bausch Health US, LLC | $117.23 | 2022-2024 | Aplenzin, Wellbutrin |
| Sunovion Pharmaceuticals INC. | $116.29 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.53 | 2022-2024 | Trintellix |
| Idorsia Pharmaceuticals US INC | $93.14 | 2022-2024 | Quviviq |
| Noven Therapeutics, LLC | $82.95 | 2022-2024 | Secuado, Xelstrym |
| Avanir Pharmaceuticals, INC. | $69.67 | 2022 | |
| Tris Pharma INC | $68.11 | 2023-2024 | Dyanavel Xr |
| Brainsway USA INC | $19.68 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanny Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.